Wednesday, July 2, 2025 7/2/2025

Molecular mechanism and targeting of chronic pain in sickle cell disease

Award Number: R35HL140031
ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 01/16/2018
PERIOD OF PERFORMANCE END DATE: 01/31/2025

Group Awards By:

View Award Description

Molecular mechanism and targeting of chronic pain in sickle cell disease - Our long-term goal is to advance the knowledge of the neurobiological and molecular mechanisms underlying chronic pain in sickle cell disease (SCD) and develop effective pharmacologic treatments. Pain is not only a life-long companion but also a predictor of mortality for the 100,000 Americans living with SCD, people mainly of African or Latin descent.1-3 Pain and SCD are so intimately intertwined, that African tribal words for the disease, spoken hundreds of years before Herrick described SCD in the western literature, are onomatopoeic for pain. Though it is now appreciated that SCD pain is characterized by chronic pain with episodes of acute pain,4-5 the neurobiology of chronic pain is poorly studied, not well characterized, and is refractory to currently available therapies,6-7 a century after Herrick's seminal paper.8 A great deal of research has been carried on the disease itself.9-10 Several transgenic models of SCD have been developed, including the humanized Berkeley (BERK)11 and Townes' sickle cell transgenic mice (TOW),12 both representing SCD phenotypes that closely mimics many features of severe SCD in humans.13-20 We propose to employ these well-characterized sickle cell transgenic mouse models for studying molecular and epigenetic mechanisms underlying chronic pain, which can hold much promise for a more thorough understanding of pain mechanisms in SCD and may guide development of effective therapies. This R35 program will advance the knowledge of molecular mechanisms underlying chronic pain in SCD and apply new knowledge to design and examine experimental therapeutics in mouse models of SCD. The program is designed to have flexibility that expanded or new research directions can be rapidly taken when new findings or emerging technology become available. Our research applies the power of molecular and cellular biology, pharmacology, neurobiology, epigenetics, targeted delivery, and other cutting-edge tools and we have existing research, expertise and research facility for studying sickle pain problem at molecular, cellular, and systems levels. This program will methodologically investigate chronic pain in SCD using several newly developed innovations and start to fill the void in our understanding of chronic pain of SCD. Having identified the CaMKIIα target for SC pain and recently moved a CaMKIIα inhibitor from bench to a Phase I study in patients with SCD, our team is uniquely suited to carry out research in this R35 program. Our innovation has a high probability of success given our outstanding track record, vibrant ongoing research program, and the designed flexibility in pursuing new research directions.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = -$193,525 )
2025	2024	UNIVERSITY OF ILLINOIS	809 S MARSHFIELD AVE M/C 551	CHICAGO	IL	60612	COOK	USA	Blood Diseases and Resources Research	001	7	3/19/2025	NON-COMPETING CONTINUATION	$0
2025	2024	UNIVERSITY OF ILLINOIS	809 S MARSHFIELD AVE M/C 551	CHICAGO	IL	60612	COOK	USA	Blood Diseases and Resources Research	000	7	11/25/2024	NON-COMPETING CONTINUATION	$0
2025	2024	UNIVERSITY OF ILLINOIS	809 S MARSHFIELD AVE M/C 551	CHICAGO	IL	60612	COOK	USA	Blood Diseases and Resources Research	002	7	6/13/2025	NON-COMPETING CONTINUATION	-$193,525
														Subtotal = -$193,525

Issue Date FY: 2024 ( Subtotal = $648,171 )
2024	2024	UNIVERSITY OF ILLINOIS	809 S MARSHFIELD AVE M/C 551	CHICAGO	IL	60612	COOK	USA	Blood Diseases and Resources Research	001	7	6/8/2024	NON-COMPETING CONTINUATION	$52,912
2024	2024	UNIVERSITY OF ILLINOIS	809 S MARSHFIELD AVE M/C 551	CHICAGO	IL	60612	COOK	USA	Blood Diseases and Resources Research	000	7	12/11/2023	NON-COMPETING CONTINUATION	$595,259
														Subtotal = $648,171

Issue Date FY: 2023 ( Subtotal = $661,398 )
2023	2023	UNIVERSITY OF ILLINOIS	809 S MARSHFIELD RM 520	CHICAGO	IL	60612	COOK	USA	Blood Diseases and Resources Research	001	6	3/3/2023	NON-COMPETING CONTINUATION	$66,139
2023	2023	UNIVERSITY OF ILLINOIS	809 S MARSHFIELD RM 520	CHICAGO	IL	60612	COOK	USA	Blood Diseases and Resources Research	000	6	12/19/2022	NON-COMPETING CONTINUATION	$595,259
														Subtotal = $661,398

Issue Date FY: 2022 ( Subtotal = $661,398 )
2022	2022	UNIVERSITY OF ILLINOIS	809 S MARSHFIELD RM 520	CHICAGO	IL	60612	COOK	USA	Blood Diseases and Resources Research	000	5	12/9/2021	NON-COMPETING CONTINUATION	$595,258
2022	2022	UNIVERSITY OF ILLINOIS	809 S MARSHFIELD RM 520	CHICAGO	IL	60612	COOK	USA	Blood Diseases and Resources Research	001	5	6/13/2022	NON-COMPETING CONTINUATION	$66,140
														Subtotal = $661,398

Issue Date FY: 2021 ( Subtotal = $661,398 )
2021	2021	UNIVERSITY OF ILLINOIS	809 S MARSHFIELD RM 520	CHICAGO	IL	60612	COOK	USA	Blood Diseases and Resources Research	000	4	12/17/2020	NON-COMPETING CONTINUATION	$595,258
2021	2021	UNIVERSITY OF ILLINOIS	809 S MARSHFIELD RM 520	CHICAGO	IL	60612	COOK	USA	Blood Diseases and Resources Research	001	4	5/15/2021	NON-COMPETING CONTINUATION	$66,140
														Subtotal = $661,398

Issue Date FY: 2020 ( Subtotal = $661,398 )
2020	2020	UNIVERSITY OF ILLINOIS	809 S MARSHFIELD RM 520	CHICAGO	IL	60612	COOK	USA	Blood Diseases and Resources Research	000	3	12/31/2019	NON-COMPETING CONTINUATION	$628,329
2020	2020	UNIVERSITY OF ILLINOIS	809 S MARSHFIELD RM 520	CHICAGO	IL	60612	COOK	USA	Blood Diseases and Resources Research	001	3	3/13/2020	NON-COMPETING CONTINUATION	$33,069
														Subtotal = $661,398

Issue Date FY: 2019 ( Subtotal = $661,398 )
2019	2019	UNIVERSITY OF ILLINOIS	809 S MARSHFIELD RM 520	CHICAGO	IL	60612	COOK	USA	Blood Diseases and Resources Research	000	2	1/17/2019	NON-COMPETING CONTINUATION	$661,398
														Subtotal = $661,398

Issue Date FY: 2018 ( Subtotal = $661,398 )
2018	2018	UNIVERSITY OF ILLINOIS	809 S MARSHFIELD RM 520	CHICAGO	IL	60612	COOK	USA	Blood Diseases and Resources Research	000	1	1/12/2018	NEW	$661,398
														Subtotal = $661,398

Grand Total All Awards = $4,423,034

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Molecular mechanism and targeting of chronic pain in sickle cell disease

Award Number: R35HL140031

ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 01/16/2018

PERIOD OF PERFORMANCE END DATE: 01/31/2025

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer